2019
DOI: 10.1111/1346-8138.14801
|View full text |Cite
|
Sign up to set email alerts
|

Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: A case report and review of the published works

Abstract: Morphea profunda refers to inflammatory and sclerotic lesions that start primarily from the deep dermis, subcutaneous fat and fascia. Its pediatric case published work is limited. Here, we report the case of an 8‐year‐old girl with a 5‐year history of multiple subcutaneous nodules on her extremities and a right wrist joint contracture who had been previously diagnosed with juvenile idiopathic arthritis and treated with salazosulfapyridine, low‐dose prednisolone (PSL) and methotrexate. We performed biopsies of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 13 publications
(16 reference statements)
0
4
0
Order By: Relevance
“…To date, juvenile‐onset morphea profunda, which presents as linear or plaque type, has only rarely been reported 1,2 . No triggering events, such as vaccination and trauma, were observed in our patient in whom a plaque developed on the back.…”
Section: Figurementioning
confidence: 64%
“…To date, juvenile‐onset morphea profunda, which presents as linear or plaque type, has only rarely been reported 1,2 . No triggering events, such as vaccination and trauma, were observed in our patient in whom a plaque developed on the back.…”
Section: Figurementioning
confidence: 64%
“…Other agents including cyclosporine, hydroxychloroquine, azathioprine, retinoids, intravenous immunoglobulins, rituximab and infliximab, have all been shown effective in various case reports of severe morphea (151)(152)(153)(154)(155)(156)(157). However, their routine use is pending more definitive evidence of efficacy.…”
Section: Miscellaneousmentioning
confidence: 99%
“…Since 2019, here have been three reports on other synthetic molecules used to treat localized scleroderma (Table 2). A case report on cyclosporine A (CSA) included only one jLS patient, so findings from this and a 2016 study on 12 jLS and aLS patients [35,36] were collated. Patients were treated with CSA because of an inadequate response to prior treatment; more than 30% had pansclerotic morphea or generalized morphea.…”
Section: Other Synthetic Moleculesmentioning
confidence: 99%